Impact of left atrial volume, sphericity, and fibrosis on the outcome of catheter ablation for atrial fibrillation
Introduction To investigate the relation between left atrial (LA) volume, sphericity, and fibrotic content derived from contrast‐enhanced cardiac magnetic resonance imaging (CE‐CMR) and their impact on the outcome of catheter ablation for atrial fibrillation (AF). Methods and results In 83 patients...
Saved in:
Published in | Journal of cardiovascular electrophysiology Vol. 29; no. 5; pp. 740 - 746 |
---|---|
Main Authors | , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Wiley Subscription Services, Inc
01.05.2018
Wiley |
Subjects | |
Online Access | Get full text |
ISSN | 1045-3873 1540-8167 1540-8167 |
DOI | 10.1111/jce.13482 |
Cover
Summary: | Introduction
To investigate the relation between left atrial (LA) volume, sphericity, and fibrotic content derived from contrast‐enhanced cardiac magnetic resonance imaging (CE‐CMR) and their impact on the outcome of catheter ablation for atrial fibrillation (AF).
Methods and results
In 83 patients undergoing catheter ablation for AF, CE‐CMR was used to assess LA volume, sphericity, and fibrosis. There was a significant correlation between LA volume and sphericity (R = 0.535, P < 0.001) and between LA volume and fibrosis (R = 0.241, P = 0.029). Multivariate analyses demonstrated that LA volume was the strongest independent predictor of AF recurrence after catheter ablation (1.019, P = 0.018).
Conclusion
LA volume, sphericity, and fibrosis were closely related; however, LA volume was the strongest predictor of AF recurrence after catheter ablation. |
---|---|
Bibliography: | This work was supported by the European Union's Horizon 2020 research and innovation programme under grant agreement No. 633196 (CATCH ME project); Instituto de Salud Carlos III (ISCIII), PI16/00703; Instituto de Salud Carlos III (ISCIII), PI16/00435; Instituto de Salud Carlos III (ISCIII), CIBERCV16: CB16/11/00354; Fundació la Marató de TV3. 20152730. CERCA Programme / Generalitat de Catalunya. L. Mont., J. Brugada, and A. Berruezo are shareholders of Galgo Medical Company. Other authors: No disclosures. Funding Information DWdU and NC have contributed equally to the paper. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ISSN: | 1045-3873 1540-8167 1540-8167 |
DOI: | 10.1111/jce.13482 |